Our approach
Our experienced team apply a rigorous stock-driven investment approach that focuses on shifting company fundamentals that are mispriced by the stock market. The team works at the centre of the network of over 40 equity investment professionals, incorporates an assessment of environmental, social & governance (ESG) factors, and draws on the expertise of credit and macro investment teams across the firm. Our portfolios are driven by the teams’ highest conviction stock ideas supported by high levels of corporate engagement and rigorous risk oversight.
Benefits
Our range of global equity funds aims to deliver capital growth, income and responsible investment outcomes for our clients.
Key risks
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency exchange rates. Investors may not get back the original amount invested.
Need more information?
For further information, please contact our investment sales team.
Explore our equities range
Equities views
Equities and COVID-19: Now is not the time to double-down on uncertainty
21 May 2020
As the effects of COVID-19 continue to rip through societies and economies, Trevor Green explains why adding uncertainty on top of uncertainty is never a good investment strategy. He outlines three critical, but simple, rules for navigating the current equity market.
Read more
COVID-19: The impact on global equities
28 Apr 2020
As the coronavirus pandemic wreaks havoc on global economies, Giles Parkinson assesses the impact across equity markets and the longer-term implications for investors.
Read more
Size matters: Will COVID-19 lead to a concentration of corporate power?
22 Apr 2020
The fallout from the coronavirus pandemic could see large firms cement their dominance over weaker rivals. We examine the implications for investors.
Read more
Are investors too complacent about the coronavirus?
21 Feb 2020
In the latest of our editorial series, Link, AIQ brings members of Aviva Investors’ investment strategy, equity and debt teams together to discuss the prospects for financial markets and the world economy in the face of the coronavirus epidemic.
Read more
Multi-asset allocation views: Why the bull run in global equities could continue
12 Feb 2020
Sunil Krishnan discusses the conditions for a continued rise in global equities, the potential of Japanese and US equities to outperform from a regional perspective, and some attractive features of emerging markets – particularly Brazil – which may have been overlooked.
Read more
In a complex market, investors need to connect information signals more effectively
19 Nov 2019
A growing body of research suggests equity investors are poor at recognising the connections and interrelationships between companies. A fresh approach is needed, argues Mikhail Zverev, head of global equities at Aviva Investors.
Read more
5G: Anatomy of an equity investment idea
11 Nov 2019
The evolution of wireless technology has fuelled a host of new mobile applications and helped propel companies such as Netflix. 5G, its next iteration, promises speeds up to 20 times faster than the current 4G. But to think only in terms of speed severely underestimates 5G’s potential to fundamentally transform the business landscape – though not without tremendous risk.
Read more
Back to the future: Dr Eric Topol on AI in healthcare
3 Oct 2019
In the final article in our series on healthcare, we speak to the renowned cardiologist and author Eric Topol about his new book, Deep Medicine.
Read more
Substance over style?
30 Sep 2019
Why an agnostic approach beats equity style biases.
Read more
Big Tech bets on healthcare
25 Sep 2019
In the third of a four-part series on healthcare, we focus on technology. New tech innovations promise to deliver better treatments and cost efficiencies – but concerns over data protection and flawed AI persist.
Read more
Biotech disrupters shake up the drug discovery business
18 Sep 2019
In the second of a four-part series on healthcare, we look at how competition between Big Pharma, Chinese biotech and Silicon Valley is transforming the landscape of drug discovery.
Read more
Investors must hold bad bosses to account
16 Sep 2019
Institutional shareholders need to be as agile and active as private equity in dealing with failures of leadership.
Read more
Medicine, politics and investing: Tensions abound
12 Sep 2019
In the first of a four-part series on global healthcare, we look at why the sector is likely to take centre stage in the 2020 US elections and what this means for investors.
Read more
As China soars, emerging market investors need a rethink
21 Aug 2019
With China set to dominate EM equity indices over the coming decades, investors need to adjust their approach to the asset class, argues Alistair Way.
Read more
BP vote demonstrates power of engagement
28 Jun 2019
As climate change rises up the political agenda throughout the West and beyond, shareholders have an important role to play in limiting global fossil fuel consumption by pressuring oil companies to amend their strategies, argues Sora Utzinger.
Read more
'Fairtrade for finance' should be a badge of honour - not a rubber stamp
21 Jun 2019
A Fairtrade-style kitemark for responsible investment is in the pipeline. Properly implemented, the initiative should improve industry standards on ESG, writes Steve Waygood.
Read more